- Home
- RIGL vs CTO Comparison
RIGL vs CTO Comparison
Compare RIGL & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- CTO
- Stock Information
- Founded
- RIGL 1996
- CTO 1902
- Country
- RIGL United States
- CTO United States
- Employees
- RIGL N/A
- CTO N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- CTO Real Estate Investment Trusts
- Sector
- RIGL Health Care
- CTO Real Estate
- Exchange
- RIGL Nasdaq
- CTO Nasdaq
- Market Cap
- RIGL 486.4M
- CTO 580.9M
- IPO Year
- RIGL 2000
- CTO N/A
- Fundamental
- Price
- RIGL $20.99
- CTO $19.78
- Analyst Decision
- RIGL Buy
- CTO Strong Buy
- Analyst Count
- RIGL 5
- CTO 4
- Target Price
- RIGL $34.80
- CTO $21.50
- AVG Volume (30 Days)
- RIGL 216.6K
- CTO 220.6K
- Earning Date
- RIGL 03-04-2025
- CTO 02-20-2025
- Dividend Yield
- RIGL N/A
- CTO 7.68%
- EPS Growth
- RIGL N/A
- CTO N/A
- EPS
- RIGL 0.22
- CTO 0.61
- Revenue
- RIGL $157,374,000.00
- CTO $118,662,000.00
- Revenue This Year
- RIGL $51.34
- CTO N/A
- Revenue Next Year
- RIGL $15.75
- CTO $13.12
- P/E Ratio
- RIGL $94.25
- CTO $32.77
- Revenue Growth
- RIGL 21.65
- CTO 16.61
- 52 Week Low
- RIGL $7.48
- CTO $16.16
- 52 Week High
- RIGL $29.82
- CTO $21.15
- Technical
- Relative Strength Index (RSI)
- RIGL 55.77
- CTO 53.69
- Support Level
- RIGL $20.98
- CTO $19.26
- Resistance Level
- RIGL $23.01
- CTO $19.77
- Average True Range (ATR)
- RIGL 1.40
- CTO 0.35
- MACD
- RIGL 0.31
- CTO 0.04
- Stochastic Oscillator
- RIGL 70.13
- CTO 73.26
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a Florida-based real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.